argenx is a Belgian-Dutch biotech that sells Vyvgart, a treatment for the autoimmune condition myasthenia gravis, and is testing it in other diseases.
New approved uses for Vyvgart and clinical trial readouts are the main catalysts. It does not yet earn a steady profit.